Balint, Milena Todorović (57140127400)Milena Todorović (57140127400)BalintLemajić, Nikola (58669226700)Nikola (58669226700)LemajićJurišić, Vladimir (6603015144)Vladimir (6603015144)JurišićPantelić, Sofija (58670044000)Sofija (58670044000)PantelićStanisavljević, Dejana (23566969700)Dejana (23566969700)StanisavljevićKurtović, Nada Kraguljac (36195445000)Nada Kraguljac (36195445000)KurtovićBalint, Bela (7005347355)Bela (7005347355)Balint2025-07-022025-07-022024https://doi.org/10.1016/j.tranon.2023.101811https://www.scopus.com/inward/record.uri?eid=2-s2.0-85175204274&doi=10.1016%2fj.tranon.2023.101811&partnerID=40&md5=6e02fc37e686441d31753dd91007f42ahttps://remedy.med.bg.ac.rs/handle/123456789/11675Background: Plerixafor is a bicyclam molecule with the ability to reversibly bind to receptor CXCR-4 thus leading to an increased release of stem cells (SC) into the circulation. This study aims to evaluate the efficacy of G-CSF plus plerixafor versus G-CSF alone mobilizing regimens on the basis of CD34+ cell yield and engraftment kinetics following hematopoietic SC transplants. Methods: The study incorporated 173 patients with plasma cell neoplasms (PCN), Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), undergoing mobilization and following autologous SC-transplant. For patients with mobilization failure and those predicted to be at risk of harvesting inadequate CD34+ yields (poor-responders), plerixafor was administered. Data was collected and compared in relation to the harvesting protocols used, cell quantification, cell-engraftment potential and overall clinical outcome. Results: A total of 101 patients received plerixafor (58.4 %) and the median CD34+increase was 312 %. Chemotherapy-mobilized PCN-patients required less plerixafor administration (p = 0.01), no difference was observed in lymphoma groups (p = 0.46). The median CD34+cell yield was 7.8 × 106/kg bm. Patients requiring plerixafor achieved lower, but still comparable cell yields. Total cell dose infused was in correlation with engraftment kinetics. Patients requiring plerixafor had delayed platelet engraftment (p = 0.029). Conclusions: Adequately selected plerixafor administration reduces "mobilization-related-failure" rate and assure a high-level cell dose for SC transplants, with superior "therapeutic-potential" and safety profile. The mobilization strategy that incorporates "just-in-time" plerixafor administration, also leads to a reduction of hospitalization days and healthcare resource utilization. For definitive conclusions, further controlled/larger clinical trials concerning correlation of CD34+ cell count/yield, with hematopoietic reconstitution are required. © 2023Autologous transplantationCD34⁺ cell mobilizationCytokinesG-CSFPlerixafor